Stock Track | Novavax Plummets 5.04% Intraday on FDA Vaccine Composition Uncertainty

Stock Track05-28

Novavax's stock plummeted 5.04% during intraday trading on Thursday, as investors reacted to regulatory uncertainty surrounding the composition of COVID-19 vaccines for the upcoming season.

The U.S. FDA's advisory panel is meeting to vote on whether COVID-19 vaccines for the 2026-2027 immunization campaign should target the dominant XFG variant, with staff members raising concerns about limited data on currently circulating strains. This regulatory uncertainty comes at a time when vaccine regulation has been described as being in a "state of limbo" following court interventions.

Novavax, whose protein-based COVID shot takes longer to manufacture compared to mRNA alternatives, faces particular challenges in this uncertain environment. While partner Sanofi has indicated it is manufacturing XFG-targeting Nuvaxovid vaccine as its single global COVID-19 product for the 2026-27 season, the FDA's final decision and timing could significantly impact Novavax's production planning and market position.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199656658?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199656658","market":"hk","top_or_hot":-1,"title":"Stock Track | Novavax Plummets 5.04% Intraday on FDA Vaccine Composition Uncertainty","media":"Stock Track","content":"<p>Novavax's stock plummeted 5.04% during intraday trading on Thursday, as investors reacted to regulatory uncertainty surrounding the composition of COVID-19 vaccines for the upcoming season.</p><p>The U.S. FDA's advisory panel is meeting to vote on whether COVID-19 vaccines for the 2026-2027 immunization campaign should target the dominant XFG variant, with staff members raising concerns about limited data on currently circulating strains. This regulatory uncertainty comes at a time when vaccine regulation has been described as being in a \"state of limbo\" following court interventions.</p><p>Novavax, whose protein-based COVID shot takes longer to manufacture compared to mRNA alternatives, faces particular challenges in this uncertain environment. While partner Sanofi has indicated it is manufacturing XFG-targeting Nuvaxovid vaccine as its single global COVID-19 product for the 2026-27 season, the FDA's final decision and timing could significantly impact Novavax's production planning and market position.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novavax Plummets 5.04% Intraday on FDA Vaccine Composition Uncertainty</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novavax Plummets 5.04% Intraday on FDA Vaccine Composition Uncertainty\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-28 21:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax's stock plummeted 5.04% during intraday trading on Thursday, as investors reacted to regulatory uncertainty surrounding the composition of COVID-19 vaccines for the upcoming season.</p><p>The U.S. FDA's advisory panel is meeting to vote on whether COVID-19 vaccines for the 2026-2027 immunization campaign should target the dominant XFG variant, with staff members raising concerns about limited data on currently circulating strains. This regulatory uncertainty comes at a time when vaccine regulation has been described as being in a \"state of limbo\" following court interventions.</p><p>Novavax, whose protein-based COVID shot takes longer to manufacture compared to mRNA alternatives, faces particular challenges in this uncertain environment. While partner Sanofi has indicated it is manufacturing XFG-targeting Nuvaxovid vaccine as its single global COVID-19 product for the 2026-27 season, the FDA's final decision and timing could significantly impact Novavax's production planning and market position.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"","article_id":"1199656658","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199656658","pubTimestamp":1779975862,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novavax's stock plummeted 5.04% during intraday trading on Thursday, as investors reacted to regulatory uncertainty surrounding the composition of COVID-19 vaccines for the upcoming season.The U.S....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"个股追踪|诺瓦瓦克斯盘中暴跌5.04%受FDA疫苗成分不确定性影响","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"Novavax's stock plummeted 5.04% during intraday trading on Thursday, as investors reacted to regulatory uncertainty surrounding the composition of COVID-19 vaccines for the upcoming season.The U.S. FDA's advisory panel is meeting to vote on whether COVID-19 vaccines for the 2026-2027 immunization campaign should target the dominant XFG variant, with staff members raising concerns about limited data on currently circulating strains. This regulatory uncertainty comes at a time when vaccine regulation has been described as being in a \"state of limbo\" following court interventions.Novavax, whose protein-based COVID shot takes longer to manufacture compared to mRNA alternatives, faces particular challenges in this uncertain environment. While partner Sanofi has indicated it is manufacturing XFG-targeting Nuvaxovid vaccine as its single global COVID-19 product for the 2026-27 season, the FDA's final decision and timing could significantly impact Novavax's production planning and market position.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199656658","isCrawlerRequest":true}